Controlling Pharmaceutical Risks: Science, Cancer, and the Geneticization of Drug Testing

In this insightful work, John Abraham and Rachel Ballinger delve into the evolving landscape of pharmaceutical risk management, particularly in relation to drug testing practices that have emerged since the late 1990s. They explore the intricate interplay between scientific advancements and the burgeoning field of genetics, examining how these developments have reshaped our understanding of drug efficacy and safety.

By investigating real-world case studies, the authors illuminate the complexities surrounding the approval and regulation of new medications. Their analysis reveals both the potential benefits and the inherent challenges posed by genetic-based testing methods, emphasizing the implications for patients, healthcare professionals, and the pharmaceutical industry alike.

With a clear, engaging narrative, this book invites readers to consider critical questions about the future of drug testing and the ethical dimensions of geneticization in medicine. Abraham and Ballinger skillfully balance expert knowledge with accessible writing, making this work essential for anyone interested in the intersection of science, medicine, and policy.